Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Cash flows from operating activities:    
Net income $ 4,465 $ 2,367
Adjustments to reconcile net income to net cash provided by (used in) operating activities:    
Adjustment for income from EIR method purchased receivables 4,021 1,743
Stock-based compensation expense 2,281 1,983
Gains on acquisitions (3,545)  
Gain on lease termination (27)  
Income tax expense 1  
Common stock contribution to 401(k) 124 141
Amortization of intangible assets 892 544
Depreciation 3 3
Accretion of long-term debt discount and debt issuance costs 332 427
Non-cash lease expense 17 17
Change in fair value of equity securities (112) 1,147
Change in fair value of available-for-sale debt securities classified as cash equivalents 66 45
Change in fair value of derivatives (12)  
CVR liability working capital adjustment 131  
Changes in assets and liabilities:    
Trade and other receivables, net 325 (3,705)
Prepaid expenses and other assets 753 1,176
Accounts payable and accrued liabilities (2,628) (3,265)
Operating lease liabilities (656) (108)
Unearned revenue recognized under units-of-revenue method (310) (317)
Net cash provided by operating activities 6,121 2,198
Cash flows from investing activities:    
Net cash, cash equivalents, and restricted cash acquired in Generation Bio acquisition 8,458  
Payment of contingent consideration related to LAVA CVR (2,141)  
Payments of consideration under RPAs, AAAs, and CPPAs   (8,000)
Receipts under RPAs, AAAs, and CPPAs 235 1,307
Net cash provided by (used in) investing activities 6,552 (6,693)
Cash flows from financing activities:    
Principal payments - debt (6,391) (5,066)
Debt issuance costs and loan fees paid in connection with long-term debt (80)  
Payment of preferred stock dividends (1,424) (1,368)
Repurchases of common stock (264) (545)
Proceeds from exercise of options and other share-based compensation 565 325
Taxes paid related to net share settlement of equity awards (46) (240)
Net cash used in financing activities (7,640) (6,894)
Net increase (decrease) in cash, cash equivalents, and restricted cash 5,033 (11,389)
Cash, cash equivalents, and restricted cash as of the beginning of the period 133,710 106,416
Cash, cash equivalents, and restricted cash as of the end of the period 138,743 95,027
Supplemental cash flow information:    
Cash paid for interest 5,555 6,078
Cash paid for taxes   277
Non-cash investing and financing activities:    
Accrual of contingent value rights liability in the Generation Bio acquisition 4,583  
Transaction costs in connection with Generation Bio acquisition included in accounts payable and accrued expenses 35  
Adjustment to the contingent value rights liability soon after the acquisitions 229  
Reclassification of liability awards to equity classified 3,509  
Preferred stock dividend accrual $ 1,452 $ 1,368